Ammonaps (sodium phenylbutyrate) vs Clenbuterol ()

Ammonaps (sodium phenylbutyrate) is a medication used to treat urea cycle disorders by helping remove excess ammonia from the body, which is especially important for patients with certain genetic disorders that impair the urea cycle. Clenbuterol, on the other hand, is a bronchodilator that is often used to treat breathing disorders such as asthma, and it is not approved for this use in the United States, although it is used in some other countries. When deciding between these two medications, it is essential to consider the intended use: Ammonaps is for managing a specific metabolic disorder, while Clenbuterol is aimed at respiratory issues, and their use is not interchangeable.

Difference between Ammonaps and Clenbuterol

Metric	Ammonaps (sodium phenylbutyrate)	Clenbuterol
Generic name	Sodium phenylbutyrate	Clenbuterol
Indications	Urea cycle disorders	Asthma, COPD (off-label for weight loss and performance enhancement)
Mechanism of action	Converts to phenylacetate which conjugates with glutamine to form phenylacetylglutamine, thereby reducing ammonia levels.	β2 agonist; increases muscle mass and reduces body fat by increasing muscle protein synthesis and lipolysis.
Brand names	Ammonaps, Buphenyl	Dilaterol, Spiropent, Ventipulmin
Administrative route	Oral	Oral, inhalation
Side effects	Body odor, headache, nausea, vomiting, amenorrhea, irregular menstruation	Tremors, headache, hyperactivity, insomnia, tachycardia, palpitations, muscle cramps
Contraindications	Hepatic encephalopathy, hypersensitivity to phenylbutyrate or its metabolites	Cardiac arrhythmias, tachycardia, thyrotoxicosis, myocardial infarction
Drug class	Urea cycle disorder agent	β2 agonist
Manufacturer	Horizon Pharma	Varies by brand and region

Efficacy

Ammonaps (Sodium Phenylbutyrate) in ALS

Ammonaps, known generically as sodium phenylbutyrate, is a medication traditionally used in the treatment of urea cycle disorders. Its efficacy in Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease, is an area of ongoing research. Sodium phenylbutyrate is believed to exert a neuroprotective effect by reducing neuronal stress and modulating gene expression. However, the specific efficacy of Ammonaps in ALS patients requires further clinical evaluation, as current evidence is limited and primarily derived from preclinical studies and small clinical trials.

Clenbuterol in ALS

Clenbuterol is a sympathomimetic amine commonly used for its bronchodilator effects in conditions like asthma. Its off-label use in ALS is based on its potential to promote muscle growth and slow muscle atrophy, which are significant concerns in ALS progression. Despite its theoretical benefits, the efficacy of clenbuterol in ALS patients has not been robustly demonstrated. Clinical trials are needed to ascertain its safety and effectiveness in this patient population, as the current data is not sufficient to support its routine use for ALS.

Challenges in Assessing Efficacy for ALS

Assessing the efficacy of treatments like Ammonaps and clenbuterol in ALS is challenging due to the variability in disease progression and the lack of large-scale, definitive clinical trials. ALS is a heterogeneous condition with a complex pathophysiology, making it difficult to measure the impact of therapeutic interventions. Moreover, the primary outcomes for efficacy in ALS trials, such as survival and functional decline, require extended observation periods, which complicates the assessment process.

Current Research and Future Directions

Current research on the efficacy of Ammonaps and clenbuterol in ALS is ongoing, with several studies investigating their potential benefits. Future clinical trials are essential to establish their role in the management of ALS. These trials will need to be well-designed, with adequate sample sizes and appropriate endpoints to provide conclusive evidence. Until more substantial data is available, the use of Ammonaps and clenbuterol for ALS remains experimental, and treatment decisions should be made on a case-by-case basis, considering the potential risks and benefits.

Regulatory Agency Approvals

Ammonaps

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Therapeutic Goods Administration (TGA), Australia

Clenbuterol

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Access Ammonaps or Clenbuterol today

If Ammonaps or Clenbuterol are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Ammonaps

Buy Clenbuterol

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: